NCT02074800View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Healthy
Interventions
DRUG

CNTO 328 (Sp2/0-derived)

Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.

DRUG

CNTO 328 (CHO-derived)

Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.

DRUG

Placebo

Participants will receive a single-dose of matching placebo intravenously in Part 1.

Trial Locations (2)

Unknown

Lincoln

Neptune City

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY